报告期内，公司持续推进研发创新。仿制药方面，8个品种视同通过一致性评价，获得3项临床批件，阿昔莫司原料药 DMF转A，完成11个仿制 药申报；创新药方面，重点进行小核酸药物及核酸类药物递送系统的研发，其中FY101注射液项目获得药物临床试验批准。 资料显示，北京福元医药股份有限公司2022年6月30日上市，主要从事药品制剂及医疗器械的研发、生产和销售。 8月4日晚间，福元医药也披露了股价异动公告称，公司关注到近期市场对创新药业务关注较高， 公司的1类创新药FY101尚处于临床试验阶段， 试验能否成功还存在重大不确定性。 实际上，福元医药是以仿制药起家。据年报介绍，公司拥有多个国内首仿药物如复方α-酮酸片、奥美沙坦酯片、盐酸曲美他嗪片、氯沙坦钾氢 氯噻嗪片、盐酸莫西沙星片等。 截至报告期末，公司共获得制剂境内药品注册批件209个。公司产品纳入国家医保目录品种 共126个，其中医保甲类品种共48个，国家基本药物 目录品种54个；公司19个药品制剂主要产 品，均已被纳入国家医保目录。 二级市场上，截至18日收盘，福元医药股价站上31.61元/股高峰。 拉长时间线来看，自4月9日股价低点以来，不到四个月的时间内，公司 ...

Group 1: Collaboration and Product Development - The company has maintained a nearly ten-year partnership with Daiichi Sankyo, expanding from a single product in 2015 to six products, including Olmesartan Medoxomil tablets and others, with a focus on cardiovascular treatments [2][3] - The company plans to continue expanding collaborations with Japanese firms, particularly in the cardiovascular treatment sector [2] Group 2: Market Performance and Sales - After the centralized procurement of Injection Multivitamins (12), prices decreased, but sales volume increased, with a 40% growth in sales volume and over 1.1 billion CNY in revenue in 2024 [3] - The company holds over 80% market share in the Injection Multivitamins (12) market, with three manufacturers currently competing [3] - Sales of the product "Dipeptide Injection" have shown a stable growth of nearly 10% in 2024 [4] Group 3: Product Portfolio and Future Prospects - Core products from the subsidiary Pude Pharmaceutical include Ginkgo Biloba Injection and others, which have maintained strong market positions [3] - The product "Anbrain Pills" achieved a revenue of 182 million CNY in 2024, an increase of over 80% year-on-year, with significant growth potential due to its unique market position [7] - The company has over 20 projects under research, focusing on differentiated products in areas like cardiovascular and orthopedic treatments [9] Group 4: Financial Performance and Challenges - The company's revenue for 2024 was 2.441 billion CNY, a decrease of 7.06% year-on-year, primarily due to strategic decisions affecting product procurement [9] - Total assets have declined due to measures taken to repay bank loans and dispose of idle assets [9] - The company reported a goodwill of 369 million CNY as of the end of 2024, with no signs of impairment [9] Group 5: Management Structure - The company's board consists of six members, with Shen Zhenyu as the chairperson and Guo Lei Feng as the general manager [10] - The management model adheres to legal regulations, with daily operations managed by the core management team [10]